期刊文献+

慢病毒介导SHCBP1低表达对黑色素瘤B16细胞增殖的影响 被引量:2

The effect of lentivirus-mediated down-regulation of SHCBP1 on the proliferation of melanoma B16 cells
下载PDF
导出
摘要 构建Shcbp1慢病毒干扰载体,探究SHCBP1在黑色素瘤B16细胞中的生物学功能。通过设计靶向干扰小鼠Shcbp1基因的shRNA-1和shRNA-2以及对照序列shRNA-NC,连接至慢病毒骨架载体,利用HEK293T细胞包装慢病毒颗粒,侵染B16细胞,检测干扰效率,并通过CCK-8和流式细胞术检测细胞活力和细胞周期。利用Western Blot检测增殖相关基因的表达。结果显示:敲低Shcbp1显著抑制B16细胞增殖;流式细胞术检测结果发现,敲低Shcbp1将B16细胞阻滞在G1期;ERK1/2的磷酸化水平降低,P21的表达水平升高。结果表明SHCBP1可能通过ERK1/2信号通路抑制P21的转录,加速B16细胞从G1到S期进程。 To construct Shcbp1 lentiviral interference vector to explore the biological function of SHCBP1 in melanoma B16 cells,first,the shRNA-1 and shRNA-2 that target to interfere with the mouse Shcbp1 gene and the control sequence shRNA-NC were designed and connected to the lentiviral backbone vector,HEK293 cells were used to package the lentiviral particles to infect B16 cells,the interfer-ence efficiency was tested and CCK-8 and flow cytometry were used to detect cell viability and cell cycle.Western Blot was used to de-tect the expression of proliferation-related genes.The results showed that knockdown of Shcbp1 significantly inhibited the proliferation of B16 cells;flow cytometry results showed that knockdown of Shcbp1 blocked B16 cells in the G1 phase;the phosphorylation level of ERK1/2 decreased and the expression level of p21 increased.These results indicate that SHCBP1 may inhibit the transcription of P21 through the ERK1/2 signaling pathway and accelerate the progress of B16 cells from G1 to S phase.
作者 孙志阳 冯光 雷静静 唐铖铖 孙晨皓 王令 路宏朝 SUN Zhiyang;FENG Guang;LEI Jingjing;TANG Chengcheng;SUN Chenhao;WANG Ling;LU Hongzhao(School of Biological Science Technology and Engineering,Shaanxi University of Technology,Hanzhong 723001,China)
出处 《生物学杂志》 CAS CSCD 北大核心 2022年第1期11-16,共6页 Journal of Biology
基金 陕西省教育厅科技计划项目(No.20JK0570)。
关键词 SHCBP1 细胞增殖 B16细胞 慢病毒干扰 Shcbp1 cell proliferation B16 cell lentiviral interference
  • 相关文献

参考文献6

二级参考文献58

  • 1安菊生,吴令英,李宁,李斌,俞高志,刘丽影.生殖系统原发性恶性黑色素瘤42例临床分析[J].中华妇产科杂志,2007,42(5):320-324. 被引量:13
  • 2Giblin AV, Thomas JM. Inciden mortality and survival in cutaneous melanoma [ J ]. J Plast Reconstr Aesthet Surg, 2007,60( 1 ) :32 -40.
  • 3Coit D, Andtbacka R, Anker C J, et al. Melanoma [ J ]. J Natl Compr Canc Netw,2012,10:366 - 400.
  • 4Luce JK, Thurman WG, Isaacs BL, et al. Clinical trials with the antitumor agent 5-( 3, 3-dimethyl-l-triazeno) imidazole-4-carboxamide ( NSC-45388 ) [ J ]. Cancer Chemother Rep, 1970,54 (2) : 119 - 124.
  • 5Nathanson L, Wolter J, Horton J, et al. Characteristics of rognosis and response to an imidazole carboxamide in malignant elanoma [ J]. Clin Pharmacol Ther, 1971,12 (6) :955 -962.
  • 6Costanza ME, Nathanson L, Lenhard R, et al. Therapy of alignant melanoma with an imidazole carboxamide and bischlo-roethyl nitrosurea [ J ] Cancer, 1972,30 ( 6 ) : 1457 - 1461.
  • 7Lens MB, Eisen TG. Systemic chemotherapy in the treatment of malignant melanoma [ J ]. Expert Opin Pharmacother, 2003,4 ( 12 ) : 2205 - 2211.
  • 8Bleehen NM, Newlands ES, Lee SM,et al. Cancer research ampaign phase l/ trial of temozolomide in metastatic melanoma[ J]. J Clin Oncol, 1995,13 (4) :910 - 913.
  • 9Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase m study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma [ J]. J Clin Oncol, 2000,18 ( 1 ) : 158 - 166.
  • 10Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma : final results of a randomised phase III study ( EORTC 18032 ) [ J ]. Eur J Cancer, 2011,47 (10) : 1476 - 1483.

共引文献248

同被引文献12

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部